Sign up
Tech Capital

Polarean Imaging updates on clinical trials ahead of investor symposium

Polarean Imaging PLC's (LON:POLX) chief executive Richard Hullihen tells Proactive London's Andrew Scott the enrolment of the final few patients for clinical testing of its drug-device combination for MRI lung scans will soon begin at a third trial site.

They've so far enrolled 85.4% of the required number of patients in the lung transplant pathway and 62.5% for the lung resection pathway.

This is up from 80% and 50% in mid-May.

 

View full POLX profile View Profile
View All

© tech Capital 2019

Tech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed tech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Tech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.